Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes

The research work attempted to answer the question whether an effective personalized glucose-lowering therapy, particularly with metformin, is possible in patients with type 2 diabetes based on single nucleotide polymorphism of the three genes (endothelial nitric oxide synthase, 8-oxoguanine DNA glycosylase and p53). Metformin efficacy could depend, in particular, on the presence of polymorphism in these genes